American Urogynecological Society (AUGS), 197
anal sphincter dysfunction, 206
anchoring device, 36–37, 86, 88
anorectal angle (ARA), 44, 204, 210
anorectal junction (ARJ), 204, 210
anorectal manometry, 205–206
anterior compartment, 110, 145, 180
correction rates for, 177
distal, 34
division, 202
prolapse, 5, 203, 215, 218
anterior midline defect repair, technique for, 114–115
anterior superior iliac spine (ASIS), 85
anterior vaginal wall, 31
prolapse of, 3, 142
anti-incontinence procedures/surgery, 75, 138, 144, 151, 226, See also incontinence procedures anus, 44
apical prolapse, 7, 8, 59, 101, 109, 120, 127
asymptomatic, 159
laparoscopic sacrocolpopexy and, 126
ligamentopexy repair of, 162
management of, 50, 218
post-hysterectomy, 110
post-hysterectomy vaginal, 42
post-operative outcomes for correction of, 166–168
postpartum and, 98
risk of reoperation for, 97
robotic surgery and, 55
sacral fixation of, 132
suture material used in, 71
anterior, 39–40, 42, 44, 45, 65
blood vessels and, 39
nerves and, 39
activity restrictions, 2
adhesiolysis, 85, 96, 111, 208, 217
adenza, the, 188–189
structures of, 156
treatment of, 86–87
allografts, 71, 215
American Association of Gynecologic Laparoscopists (AAGL), 155, 191
American College of Obstetricians and Gynecologists, 108, 189, 229
Committee Opinion, 221
American College of Surgeons National Surgical Quality Improvement Program database, 108
Avaulta Plus transvaginal mesh, 216
Baden Walker classification, 93, 97, 145
Behnia-Willison, F., 145
Big data, randomized trials and, 20
bilateral salpingo-oophorectomy (BSO), 86
biofeedback treatment, 207
bipolar energy, 33
bladder, 43
catheterization of bladder injuries, 104, 173
diary, 129, 136
flap, 31, 46, 85, 87, 88, 157
Foley balloon, 88
time of the, 137, 191
injuries and mesh attachment, 62
injuries to, 59, 63, 131, 160, 209, 217–218
injuries, data on, 190
injuries, intraoperative, 96
injuries, risk of, 43, 66
injuries, thermal, 87
overactive bladder (OAB), 3, 7, 194
syndrome, 129
symptoms, 73
blood vessels
anterior abdominal wall and, 39
pelvis and, 44–45
body composition, extremes of, 242–243
body habitus, 159–160, 208
body posture, in laparoscopic surgery, 25
Boston Scientific, ProtoGen mesh, 216
bowel dysfunction, 73, 93, 94, 110
involvement in sacrocolpopexy mesh complications, 65
mechanical preparation, 208
obstruction, 126, 173
obstruction due to mesh adhesion, 217–218
small bowel obstruction, 62, 67, 73, 108
small bowel obstruction, postoperative, 96
bowel injury, 59, 61, 64, 64, 66, 81, 120, 160, 172, 173, 179, 189, 217, 242
rectal, 103
risk of, 44, 120
small, 126
Breisky-Navratil retractor, 115, 151
description of, 116
British Society of Urogynaecology (BSUG), 190
Breisky-Navratil retractor, 115, 151
description of, 116
British Society of Urogynaecology (BSUG), 190
Burch colposuspension, 43, 44, 45, 121, 127, 129, 131, 143, 194, 195, 196, 217, 219
Burch retropubic urethropexy, 198
Burch urethropexy, 8, 42, 142, 144
modified, 131
paravesical space and, 46
prior, 142
vs MUS, 198
burping, 244
cadaveric training/studies, 32, 34, 36, 37, 47, 53, 56
Cambridge Medical Robotics, 236
candour, duty of, 14
carbon dioxide absorption, 1
cardiovascular function, changes in, 1
CARE trial/study (E-Care), 109, 110, 131, 195, 197
analysis of, 196
outcomes of, 196
Carter-Thomason CloseSure System, 159
catheters
Foley, 63, 65, 88, 121, 126, 131, 156, 160, 225
Foley, emptying bladder with, 61
Index

French Foley, 143
postoperative management, 133
three-way Foley, 208
cave of Retzius. See Retzius, 1
hysterectomy, 85, 127, 187, See also sacrocolpopexy
choosing laparoscopic, 187
complications with, 160

ExCITE technique (Extracorporeal C-Insision Tissue Extraction), 89
Extended OPTIMAL study, 167
fallopian tubes, treatment of, 86–87
fascial sling, concomitant, 198
fetal incontinence, 203, See also prolapse
Female Sexual Function (FSFI) and Prolapse Quality of Life (P-QOL) scores, 126
fertility preservation, 98
Finnish cohort studies, 187
Foley balloon. See Foley catheter
Foley catheter, 61, 63, 65, 68, 88, 121, 126, 131, 156, 225
French, 143
fornix, 160
three-way, 208
health-related quality of life (P–QOL), 126
hypercapnic state, 1

more Information

Edited by Christian Phillips, Stephen Jeffery, Barry O’Reilly, Marie Fidelia R. Paraíso, Bruno Deval

Cambridge University Press & Assessment

© in this web service Cambridge University Press & Assessment

www.cambridge.org
hysterectomy (cont.)
concurrent, 31, 149
considerations about, 149
conversion to a laparotomy, 160
incidence of hemorrhage during, 160
indications and contra-
indications and, 155
infection, 160
laparoscopic, 155
laparoscopic subtotal, 189
laparoscopic vs abdominal, 155
laparoscopic-assisted vaginal, 159
learning curve for laparoscopic, 187
mesh erosion and, 72
mesh exposure and, 149
ovarian function and, 176
pelvic organ prolapse repair (POP) repair and, 176
postmenopausal women and, 182
preparing the patient for a laparoscopic, 155–156
robotic surgery and, 228–229
sacrocolpopexy and, 148
sacrocolpopexy with supraventricular, 149
steps of a laparoscopic, 155–159
surgical technique for vaginal, 163–164
total laparoscopic, 155
transvaginal mesh attachment and, 33–34
types of laparoscopic, 155
underlying condition for, 176
uterine cancer risk and, 176
vaginal approach, 162
women’s quality of life after, 177–178
women’s views of, 175, 179, 181
hysteroscopy, A
post-operative outcomes of, 104–106
surgical technique, 102–104
illicoccygeus muscle, 42
implants, reconstructive surgical repairs and, 70
incisional hernia formation, 2
Incontinence Impact Questionnaire, 17
incontinence procedure. See also stress urinary incontinence (SUI)
SCP and, 197
stress urinary incontinence, 199
incontinence procedures, 194–195, 196
mid-urethral slings (MUS) and, 197
incontinence surgery. See also stress urinary incontinence (SUI)
concomitant, 194, 199
indentivity, medical, 83
individualized care, 20
Initial Measurement of Patient-Reported Pelvic Floor Complaints Tool (IMPACT), 4
injuries
ureteric, 132
injuries, 190
bladder, 63
urethra, 29, 63–64
vascular, 64–65
instrumentation. See instruments
laparoscopic, 28–29
straight stick, 28–29
surgical, 111
integral theory, 129
International Consortium on Healthcare Outcome Measurement (ICHOM), 21
International Consultation on Incontinence (ICI), 93, 108
International Consultation on Incontinence Moduler Questionnaire (ICIQ), 135
International Consultation on Incontinence Questionnaire for Urinary Incontinence (ICIQ UI), 129
International Consultation on Incontinence Questionnaire for Urinary Incontinence (ICIQ-SP), 18
International Consultation on Incontinence Questionnaire—Vaginal symptoms (ICIQ-VS), 97
International Continence Society (ICS), 94, 129
International Urogynaecological Association (IUGA), 53, 92, 94, 129
terminology document, 195
internus muscles, 46
intra-abdominal blood flow, 2
intracranial pressure, increase
UIGA. See International Urogynaecological Association (IUGA)
Jarvis, Gerry, 16
Johnson and Johnson, class action lawsuit against, 82
King’s Health Questionnaire, 17
Klumpke’s palsy, 66
Koh, David, 53
Lane, Fredrick, 108
laparoscopic colposuspension, 60–61
complication rate in, 60
cystoscopic check of, 62
laparoscopic dissectors, 32
laparoscopic entry, 46, 64
assisting with the, 47
injuries caused by, 59, 81
nasogastric or orogastric tube and, 156, 208
obtaining, 18
Veress needle and, 208
laparoscopic hysterectomy adnexa and fallopian tubes treatment, 86–87
indications for, 192
learning curve for, 187
materials used in, 85–86
reasons to choose, 187
surgical steps in, 86–90
surgical team set up, 85–86
laparoscopic hysterectomy, 8
laparoscopic injuries, entry
techniques and, 27
laparoscopic mesh sacrohysterectomy (LSH), 92
laparoscopic paravaginal repair (LPVR), 142, 145
laparoscopic pectopexy, versus vagino sacrospinous fixation (SSF), 126
laparoscopic pectopexy, 126
laparoscopic sacrocolpopexy (LSC), 61, 65, 126, 148, 176, 179
complication rate in, 60
instruments used in, 111
versus transvaginal mesh, 72
laparoscopic sacrohysterectomy (LSH), 217
counselling for, 93–94
patient selection and, 93
laparoscopic screen/monitor, 25–26
laparoscopic subtotal/supraventricular hysterectomy (LSH), 191
laparoscopic surgery advantages of, 1 future of, 54
general approach to, 1
intraoperative injuries and, 2
physiologic changes in, 1
risks of, 59
single-incision (SILS), 28
laparoscopic urogynaecology, 51–52, 59
causes for litigation in, 80–82
prevention of complications in, 60
robotic surgery and, 232
surgical approach, 59
training programmes and, 67
laparoscopic-assisted vaginal hysterectomy (LAVH), 85
laparoscopy, complications of gynaecological, 59–60
laparotomy conversion to, 160
previous, 237
total hysterectomy done by, 187
lateral defect repair, technique for, 116–118
lawsuits in the UK, 78–79
Leach, Garry, 16
learning curve, the, 50–51
cost of, 51
laparoscopic urogynaecology and, 51–52
negative characteristics and, 51
other surgical procedures and, 52
outcome measures and, 51
robotic, 51
sacrocolpopexy (LSC), 59–60
sacrohysteropexy (LSH), 191
surgical skill and, 51
urogynaecology surgery and, 50–51
urology surgery and, 50–51
levator ani muscles, 39, 45, 60, 101, 142, 202, 208
levator muscles, 116, 208, 209
Level II support defects, 42
levator ani muscles, 39, 45, 60
levator muscles, 116, 208, 209
Level II support defects, 42
ligamentopexy, 163
levator ani muscles, 39, 45, 60
levator muscles, 116, 208, 209
Level II support defects, 42
ligamentopexy, 163
for apical prolapse, 162
litigation, 78–79
avoidance of, 82–83
causes for, 80–82
costs of, 83
ethical issues and, 83
pre-trial, 79–80
reasons for, 79
stages in, 79
trial, 80
Loane, Katharine, 19
local patient information leaflets (PILs), 93
LS Cl, 1
laparoscopic sacrocolpopexy (LSC)
LSH. See laparoscopic sacrohysterectomy (LSH)
Lucite vaginal stent, 86
maladies, risks of, 181
Manchester-Forthgill procedure, 93, 94
manometry, anorectal, 205–206
Marshall-Marchetti-Krantz procedure, 42, 131, 142
Mayer-Rokitansky-Kuester-Hauser syndrome, 121
McCall culdoplasty, 159
medication, 80
Medical Defence Union (MDU), 83
medical devices, problems with, 82
medical education, 50
the learning curve and, 50–51
medical indemnity, 83
medical malpractice suits, 78
Medical Outcomes Study SF-36 Health Status Profile, 17
Medical Protection Society (MPS), 83
Medical Research Council (MRC), 134
more information
978-1-009-12317-4 — Laparoscopic Urogynecology
Cambridge University Press & Assessment
www.cambridge.org
© in this web service Cambridge University Press & Assessment
medical risk factors, 2
medicine, personalized, 20
mesh
abdominally and laparoscopically placed, 217
absorbent synthetic, 71
attachment, 149
attachment of sacrocolpopexy, 152
biologic, 70–71, 73
choice of, 151
classification of, 215–216
classification of synthetic, 71
complications from using, 65–66
cost of, 216–217
erosion, 173
exposure, 149
for use in pelvic reconstructive surgery, 216
infection, 73
macroporous, 71
microporous, 71
non-absorbable synthetic, 71
planning for use of, 72
polypropylene, 70
polyvinylidene fluoride (PVDF), 71
monofilament, 123
postoperative complications and, 217
pros and cons of, 73–74
risks of using, 72–73, 217
safety and efficacy of, 216, 217
surgical factors and, 217
synthetic, 71, 75, 215–216
synthetic absorbable, 215–216
synthetic non-absorbable, 216
tansvaginal, 215
use in laparoscopic urogynecological surgery, 216–217
vaginal attachment, 151–152
mesh attachment
anterior longitudinal ligament and, 35–36
laparoscopic/robotic, 34
method of, 36
robotic, 34
sutures used for, 34
tansvaginal, 33–34
mesh erosion, 72
hysterectomy type and, 72
post-hysterectomy patients and, 72
synthetic versus biologic graft, 72
MHRA (Medicines and Health Regulatory Authority), 82
Michigan Surgical Quality Collaborative (MSQC) database, 228
mid-urethral slings (MUS), 8, 45, 59, 121, 196
comparison, 137

| medical risk factors, 2 |
| medicine, personalized, 20 |
| mesh | abdominally and laparoscopically placed, 217 |
| absorbent synthetic, 71 |
| attachment, 149 |
| attachment of sacrocolpopexy, 152 |
| biologic, 70–71, 73 |
| choice of, 151 |
| classification of, 215–216 |
| classification of synthetic, 71 |
| complications from using, 65–66 |
| cost of, 216–217 |
| erosion, 173 |
| exposure, 149 |
| for use in pelvic reconstructive surgery, 216 |
| infection, 73 |
| macroporous, 71 |
| microporous, 71 |
| non-absorbable synthetic, 71 |
| planning for use of, 72 |
| polypropylene, 70 |
| polyvinylidene fluoride (PVDF), 71 |
| monofilament, 123 |
| postoperative complications and, 217 |
| pros and cons of, 73–74 |
| risks of using, 72–73, 217 |
| safety and efficacy of, 216, 217 |
| surgical factors and, 217 |
| synthetic, 71, 75, 215–216 |
| synthetic absorbable, 215–216 |
| synthetic non-absorbable, 216 |
| transvaginal, 215 |
| use in laparoscopic urogynecological surgery, 74–75 |
| vaginal attachment, 151–152 |
| mesh attachment |
| anterior longitudinal ligament and, 35–36 |
| laparoscopic/robotic, 34 |
| method of, 36 |
| robotic, 34 |
| sutures used for, 34 |
| transvaginal, 33–34 |
| mesh erosion, 72 |
| hysterectomy type and, 72 |
| post-hysterectomy patients and, 72 |
| synthetic versus biologic graft, 72 |
| MHRA (Medicines and Health Regulatory Authority), 82 |
| Michigan Surgical Quality Collaborative (MSQC) database, 228 |
| mid-urethral slings (MUS), 8, 45, 59, 121, 196 |
| comparison, 137 |
pelvic organ prolapse (cont.)
outcomes of surgical repair
for, 176–177
pregnancies after, 106
preoperative considerations, 142
preventing future issues, 178–179
reconstructive procedures for, 207
repair, 176
risk factors for, 101–102, 163
sacrocolpopexy, 148
safety data for use in repair of, 217–218
statics on surgery in United States of America, 202
SUI and, 194
surgical outcomes repair, 179–180
surgical technique for treating, 143–145
uterine preservation during repair for, 181–183
Pelvic Organ Prolapse Quantification (POP-Q) system, 92, 93, 126, 204
examination, 5
pelvic reconstructive surgery surgical factors and, 217
pelvic reconstructive surgery, approval of mesh for use in, 216
pelvic sidewall, 48
pelvis
avascular spaces of, 45
laparoscopic view of, 40
major blood vessels of, 44–45
nerves of, 45
paracolpial space, 46–47
rectovaginal space, 46–47
retropubic space and, 45, 46
sacral promontory and, 47
surveying the, 156
vesicovaginal space and, 46
perineal rectosigmoidectomy, 207
perineorrhaphy, 94, 208, 210, 211
peritoneal closure, 133
peritoneal incision, 33
peritoneum, closure of, 125
pneumodesis, 32
pneumoperitoneum, 1, 94
risk of laparoscopy and, 2
polydioxanone (PDS) suture, 123
polyvinylidene fluoride (PVDF) monofilament mesh, 123
ports
assistant, 244
port insertion/placement of, 25, 27, 39–40, 131, 143, 156, 225
port insertion/placement of and avoiding nerve injuries, 39–40
port insertion/placement, initial, 132, 156
port insertion/placement, robotic, 225
vertical placement of, 159
posterior compartment, 5, 34, 74, 110, 208, 212
anatomy of, 202
clinical presentation, 203
postoperative support of, 2
prolapse, 46, 203, 207
prolapse, physical
structural defects of, 202
posterior defect repair, technique for, 116
posterior vaginal wall, 31
structural haemorrhage, effects of, 202
structural problems of, 207
post-hysterectomy patients
mesh erosion and, 72
postmenopausal women, 180, 190
abnormal bleeding and, 176
hysterectomy and, 101, 182
pelvic organ prolapse (POP) and, 168
uterine prolapse and, 92
postoperative activities, benefits of, 2
postoperative management, 96
pregnancies, after pelvic organ prolapse, 106
preoperative assessment, 93
counselling for LSH and, 93–94
patient selection and, 93
preoperative preparation, 11, 131–132
sacrocolpopexy, 208
surgical technique and, 94
presacral neurohormonal, risk of, 32
pre-trial, litigation, 79–80
prevesical space. See Retzius, Anders
drainage of haematoma in pelvic organ prolapse, 181–183
repair, 176
pelvic organ prolapse (POP)
and, 98
sexual, 175–176
questionnaires, part of quality-of-life (QoL), 176
randomised controlled trial (RCT), 96, 108
randomized trials, 3, 21, 108, 167–168
Cochrane review and, 108
Cochrane review of, 229
reconstructive surgery transvaginal native tissue repair, 166
vaginal native tissue, 163
rectal injury, 63
rectal intussusception, 202, 203, 205–209
rectal prolapse, 170, 173, 205–209
classification of, 170
clinical presentation, 170
contra-indications, 171
definitions and pathogenesis of, 202
medical management of, 207
multidisciplinary management of, 202
pelvic organ prolapse (POP) together, 202
risk factors for, 170
surgical techniques for treating, 170, 207–208
rectal ulcer syndrome, 170
recto-anal inhibitory reflex (RAIR), 206
rectoceles, 126–127, 202, 205
rectocele, 225
rectocele vs enterocoele, 205
formation of de novo, 126
medical management of, 207
pathogenesis of the, 202
surgical management of, 207
transvaginal repair, 207
rectoanpexy, 74. See also rectal prolapse complications from, 173
contra-indication for, 171
postoperative outcomes of, 142–143
surgical outcomes, 211–212
surgical technique, 171–173
ventral mesh, 171, 208–209
rectovaginal space, 46
rectocoele, 126–127
rectocele, 205
rectocele vs enterocoele, 205
formation of de novo, 126
medical management of, 207
pathogenesis of the, 202
surgical management of, 207
transvaginal repair, 207
sacrocolpopexy and, 229
setting up a programme for, 236
surgical steps of in urogyne- 
oclogy, ... free vaginal tape (TVT), 17, 67, 94, 129, 136, 137, 194, 198
cost and, 138
incontinence procedures and, 194, 197

sacrocolpopexy and, 229
setting up a programme for, 236
surgical steps of in urogyne- 
oclogy, ... free vaginal tape (TVT), 17, 67, 94, 129, 136, 137, 194, 198
cost and, 138
incontinence procedures and, 194, 197
tension free vaginal tape (cont.)
perforation rate, 19
statistics and, 196
stress urinary incontinence
(SUI) and, 138
vs. colposuspension, controlled trial and, 16
third arm, use of, 244, 245
total hysterectomy, 148, See also
hysterectomy
complication rates, 190–191
differences with subtotalex.
hysterectomy, 190–192
round ligaments and, 188
surgical technique for, 188–189
transvaginal mesh attachment
and, 33–34
via laparotomy, 187
total laparoscopic hysterectomy
( TLH), 85, 143
decision technique on, 89
specimen removal after, 89–90
versus hysterectomy, 28
training
cadaveric, 53, 56
experimental, 53
high fidelity, 53
low-fidelity, 53
online simulation, 53
optimising, 52–53
robotic surgery, 54–55
simulation, 53
transvaginal mesh, 108, 110,
152, 194, See also mesh
attachment, 33–34, 149, 153
attachment and PROSPECT
trial of, 97
attachment data on, 105
ban era, 127
concerns around use of, 92
insertion of, 176
litigation, 194
prolapse and, 94, 162, 215
ProteGen™ sling, 94
repair of, 108
safety of, 216
surgery, 199
transvaginal native tissue repair, 169
transvaginal NOTES (vNOTES),
28, See also vaginal
NOTES
transvaginal rectocele repair, 209
transvaginal surgery,
reconstructive, 162
transverse perinei muscles, 211
Trendelenburg position, 1, 2,
44, 61, 81, 111, 155, 156,
188, 224, 243
cardiac changes and, 1
gynaecologists and the, 26
laparoscopic hysterectomy
urology, and, 155
steep, 88
swelling and, 1
trials, 80
randomized, 21
trocars, 67, 160, 237, 243, 244
placement of, 111–112, 188,
225
robot, 237
spacing, 243
ultrasonic scalpels, 33
umbilicus, as site of entry to
total laparoscopic hysterectomy.
( TLH), 96
ureter, 42–43
ureteric injury, 59–63, 132,
190
urethra, 43
urethral bulking agent, 199
urethroplasty, 110, 134
Burch, 8, 42, 142, 143
Burch retro pubic, 198
retro pubic, 60, 194, 195, 196
Urinary Distress Inventory,
Short Form (UDI-6), 3
urinary incontinence, 3
concomitant procedure for,
199
urinary tract injury, 160
urology, 42–43
urodynamic stress incontinence
(USI), 130
urodynamic studies (UDS), 130
urogynaecological procedures/
surgery, 3, 43, 50, 236
as elective procedure, 11
benefits of laparoscopic
surgery in, 2
complications of, 13
consenting for, 12–13
laparoscopic approach to, 8
mesh use in, 74–75
patients understanding of, 14
physical evaluation before, 4
preoperative assessment, 67
before, 4
research into, 56
sacrocolpopexy and, 73
use of mesh in, 72
vaginal approach, 3
urogynaecology
laparoscopic, 51–52, 59
learning curve and, 51
minimising complications, 59
robotic surgery in benign
gynaecology, 232
robotics in, 233–234
specific advantages of
robotics in, 233
urogynaecology.
See urogynaecological
surgery.
urogynaecology
US Food and Drug
Administration, 162
US Food and Drug Agency
(FDA), 94
urine, 85, 156, 157, 189
ligation, 88
urine body amputation, 88–89
urine cancer, 181
risk of, 176
urine cornua, 41, 86, 87, 157
urine manipulators, 86, 156
urine pathology, 155, 182
concomitant hysterectomy
and, 85
incidence of, 178
later in life, 181
risk of after hysterectomy, 8
risk of future issues, 178–179
urine preservation, 92, 93, 97,
98, 175, 176, 179
Dutch women choice of, 181
risk of pelvic organ prolapse
and, 177
women's preference for,
181–183
women's quality of life and, 178
urine removal, 189, 190
urine vesicles, 88, 157–158,
189
urine-sparing procedures, 8
uterosacral ligament
hysterectomy, 167
uterosacral ligament suspension
(ULS), 3, 4, 7, 42, 43,
108, 152, 167–168, 177,
179, 233
apical prolapse correction
and, 163
hysterectomy and, 8
studies on, 166
success rates of, 167
vaginal hysterectomy with,
177
ureterovesical peritoneum, closure
of, 95
ureterovesical pouch, 244
urterus manipulator, 188
uterus, the
and womanhood, 175
sexual quality of life and, 175–176
vagina
closing the, 189
opening the, 189
vaginal apex, 159
vaginal attachment, 151–152
vaginal cuff, 151
closing the, 158–159
closure of the, 151
dehiscence, 160
vaginal dissection
and, 151
posterior, 151
vaginal ligamentopexy, 167
vaginal mesh attachment, 149
vaginal native tissue, 163
vaginal NOTES sacrocolpopexy,
152–153
patient care and, 153
vaginal paravaginal (VPVR), 145
vaginal sacrospinous fixation,
218
vaginal sacrospinous ligament
vaginal support devices, 92
vaginal surgery
benefits of laparoscopy in, 2–3
techniques, 120
vaginal suspension,
prophylactic, 168
vaginal vault prolapse. See also
prolapse, pelvic organ
prolapse ( POP)
post-hysterectomy, 34
uterine prolapse, 203
Valsalva maneuver, 5, 42, 93,
130, 142, 204
vascular injuries, 64–65
avoiding, 39–40
vaso-vagal response, 1
women's quality of life and,
175
womenhood, the uterus and,
175
development of, 85
dissection of, 88
developing the, 85, 88
Vesicovaginal pouch/space, 43,
158
vesicouterine pouch/space, 43,
188
versus hysterectomy, 28
ventral mesh recto pexy, 207
ventral recto pexy, laparoscopic
mesh sacrocolpopexy and,
208
preoperative preparation for, 208
VersaStep™, 67
vesicocolpopexy.
pharynx, 168
vaginal vault prolapse. See also
prolapse, pelvic organ
prolapse ( POP)
post-hysterectomy, 34
uterine prolapse, 203
Valsalva maneuver, 5, 42, 93,
130, 142, 204
vascular injuries, 64–65
avoiding, 39–40
vaso-vagal response, 1
women's venous thromboembolic
ingredients, 2–3
ventral mesh recto pexy, 207
ventral recto pexy, laparoscopic
mesh sacrocolpopexy and,
208
preoperative preparation for, 208
VersaStep™, 67
vesicovaginal pouch/space, 43,
46
video cystourethrography, 130
women
pelvic floor disorders in, 70
quality of life of, 177–178,
180–181
womanhood, the uterus and,
175
World Health Organisation
(WHO)
theatre checklist, 28
Wright, TP, 50, 227
Wright Learning Curve, 50
xenografts, 71, 215